PFG Advisors Increases Holdings in IQVIA Holdings Inc. (NYSE:IQV)

PFG Advisors lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 45.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,068 shares of the medical research company’s stock after acquiring an additional 1,893 shares during the quarter. PFG Advisors’ holdings in IQVIA were worth $1,192,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the company. Private Trust Co. NA boosted its stake in shares of IQVIA by 10.7% during the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock worth $115,000 after acquiring an additional 47 shares in the last quarter. Pine Valley Investments Ltd Liability Co boosted its stake in shares of IQVIA by 0.5% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock worth $2,247,000 after acquiring an additional 50 shares in the last quarter. Howard Capital Management Inc. lifted its stake in IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock valued at $225,000 after buying an additional 54 shares in the last quarter. Huntington National Bank lifted its stake in IQVIA by 7.4% in the 3rd quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock valued at $192,000 after buying an additional 56 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in IQVIA by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock valued at $1,068,000 after buying an additional 56 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on IQV. Robert W. Baird reduced their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. JPMorgan Chase & Co. reduced their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. Bank of America reduced their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Finally, Morgan Stanley upped their target price on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Trading Down 2.1 %

IQV stock opened at $181.53 on Friday. The company has a market cap of $32.01 billion, a price-to-earnings ratio of 24.20, a PEG ratio of 1.99 and a beta of 1.50. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The business has a fifty day simple moving average of $196.87 and a 200-day simple moving average of $211.38. IQVIA Holdings Inc. has a 52 week low of $179.28 and a 52 week high of $256.76.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.